ORIC Pharmaceuticals, Inc.

NasdaqGS:ORIC Stock Report

Market Cap: US$579.4m

ORIC Pharmaceuticals Dividends and Buybacks

Dividend criteria checks 0/6

ORIC Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-21.9%

Buyback Yield

Total Shareholder Yield-21.9%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Dec 12
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Aug 21
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation

Jul 29

ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value

Jul 17

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

May 08
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains

Mar 13

We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

Jan 18
We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Sep 27
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 14
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

Jan 24
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth

ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech

Oct 14

Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

Oct 08
Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?

ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09

Aug 11

ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

Jun 24
ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Mar 08
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Nov 23
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

Aug 05
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth

ORIC Pharmaceuticals EPS beats by $0.04

May 06

Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

Apr 16
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation

We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Jan 01
We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely

Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101

Dec 21

Oric Pharma prices stock offering at $23

Nov 13

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ORIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ORIC's dividend payments have been increasing.


Dividend Yield vs Market

ORIC Pharmaceuticals Dividend Yield vs Market
How does ORIC dividend yield compare to the market?
SegmentDividend Yield
Company (ORIC)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.5%
Analyst forecast (ORIC) (up to 3 years)0%

Notable Dividend: Unable to evaluate ORIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ORIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ORIC's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ORIC has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:22
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ORIC Pharmaceuticals, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Prakhar AgrawalCantor Fitzgerald & Co.
Yigal NochomovitzCitigroup Inc